CytoReason
Machine Learning for Data-driven Target Discovery and Drug Development
Startup C Health Tech & Life Sciences Est. 2016
Total Raised
$132M
C
Last Round
$80M
6 rounds
Investors
6
6 public
Team
11
51-200 employees
Confidence
100/100
News
23
articles
About
CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate. With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.
Classification
Sector
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Core Technology
BiologicalsCellsArtificial IntelligenceMachine Learning
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersLaboratories
Business Model
B2B
Tags
clinical-trialslaboratoriesartificial-intelligencehealthcare-providerspatent-pendingdrug-discoveryclinical-dataclinicsmedical-technologiesdata-analyticsdigital-healthcarebig-datapharma-companiescancermachine-learningbiotechnologybiopharmaceuticalimmunotherapyimmunologybioinformaticsmhealthautoimmune-diseasesmolecular-biologydecision-supportnatural-language-processingcells
Funding & Events
Oct 2022
Convertible Debt $30M
Pfizer (Lead), OurCrowd
May 2024
B Round Undisclosed
OurCrowd
Jun 2021
A Round $8.41M
OurCrowd (Lead)
Jul 2024
C Round $80M
Nvidia, Pfizer, OurCrowd, Thermo Fisher Scientific
Jul 2020
A Round $10.79M
OurCrowd (Lead)
Jan 2020
Seed $2.8M
PICO Venture Partners, Pontifax
News (23)
Jul 17, 2024 · en.globes.co.il
growth-positive
Israeli AI disease models co CytoReason raises $80m
InvestmentPartnersExpand
Jun 28, 2023 · pharmatimes.com
growth-positive
Momentum for Poolbeg and CytoReason's AI collaboration - PharmaTimes
Partners
Jan 24, 2023 · www.timesofisrael.com
growth-positive
Sanofi extends cooperation with Israel's CytoReason for bowel disease drug discovery
Partners
Sep 20, 2022 · www.calcalistech.com
growth-positive
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform | CTech
PartnersInvestment
Apr 12, 2022 · www.prnewswire.com
growth-positive
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
Partners
Feb 10, 2022 · www.timesofisrael.com
growth-positive
Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason
Partners
Jan 20, 2022 · techtime.co.il
growth-positive
סייטוריזן פיתחה תוכנת AI המנבאת הצלחה של ניסויים קליניים - Techtime - חדשות אלקטרוניקה והייטק
Investment
Oct 20, 2021 · www.fiercebiotech.com
N/A
Merck KGaA taps CytoReason's machine learning platform to profile immuno-oncology drug
Oct 12, 2021 · www.outsourcing-pharma.com
growth-positive
CytoReason, Summit tap into AI on Japanese drug development effort
Partners
Sep 30, 2021 · www.calcalistech.com
growth-positive
CytoReason enters Japanese market with SPI partnership
Partners
Jun 17, 2021 · www.prnewswire.com
growth-positive
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
Partners
May 19, 2021 · www.prnewswire.com
growth-positive
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
Partners
May 18, 2021 · www.timesofisrael.com
growth-positive
The secret Israeli sauce in Pfizer's new drug mix - Sponsored Content The Times of Israel
Partners
Apr 19, 2021 · www.datanami.com
AI-Powered Drug Development in a Post-COVID World
growth-positive
When can computer models replace animal trials? - Drug Discovery and Development
Customers
Mar 30, 2021 · tntribune.com
growth-positive
New Startup Helps Pfizer Create More Effective, Targeted Drugs For Patients - The Tennessee Tribune
Partners
Jul 30, 2020 · www.jpost.com
growth-positive
https://www.jpost.com/opinion/hillels-tech-corner-cytoreason-where-ai-meets-drug-development-631184
PartnersCustomers
Jul 20, 2020 · www.themarker.com
growth-positive
סייטוריזון בנבחרת הסטארטאפים 2020 של TheMarker
Investment
Mar 11, 2019 · venturebeat.com
growth-positive
Ground Breaking New Methodology Published in Nature Medicine Uncovers the Missing Numbers to the Only Clock That Really Matters in the Body - Your Immune Age
Investment
Jan 10, 2019 · en.globes.co.il
growth-positive
CytoReason teams with Pfizer on drug discovery
Partners
+ 3 more articles
Details
Product Stage
Released
Employees
51-200
Exact Count
124
Founded
2016
Registrar
515522134
Crunchbase
cytoreason
Locations
Derech Menachem Begin 132, Tel Aviv-Yafo, Israel
Links
Website
LinkedIn
Twitter
Careers
Admin
Last Update
Mar 6, 2025
Verified by
Jenny Sotnik-Talisman
Claimed
Yes
Missing
markets
Team (11)
Shai Shen-Orr
Co-founder & CSO
Founder
David Harel
Co-founder & President
Founder
Elina Starosvetsky
Co-founder & VP Experimental Biology
Founder
Ksenya Kveler
Co-founder (No longer with the company)
Founder
Yuval Kalugny
Co-founder (No longer with the company)
Founder
Eti Mitrany Rayten
CFO & Head of Corporate Strategy
Matt Levy
Chief Commercial Officer (CCO)
Yehuda Chowers
Chief Medical Officer
Adir Katz
VP R&D
Zeev Ben-Shachar
Director Of Strategic Communications
Eldad Kadari
Sr. Director, Account Management
Internal
Created by
Jenny Sotnik-Talisman (genys30@yahoo.com)
Created
2016-09-13T00:00:00.000Z
Last editor
Yanina Wainscheinker (yanina.wainscheinker@sncentral.org)